

**Washington Vaccine Association
Executive Committee Meeting**

November 30, 2023; 1:00 – 2:00 p.m. PT

- I. Attendance.** This meeting was conducted solely by webinar. Participating in all or part of the meeting were the following individuals:

Directors:

John Dunn, MD, Kaiser Permanente, Chair
Beth Harvey, MD, South Sound Pediatrics, Vice Chair
Ed Marcuse, MD, Emeritus Professor of Pediatrics, UW, Secretary
John Sobeck, MD, Regence and Asuris Health Plans

Helms & Company, Inc.:

Patrick Miller, MPH, WVA Administrative Director
Ashley Ithal, MPH, WVA Program Support
Leslie Walker, CPA, Mason+Rich, PA

Others:

Cameron Long, Esq., Leonard & Kolan
Anne Redman, Esq., Perkins Coie, Outside Counsel

WVA:

Julia Walter Zell, MA., Esq., Executive Director
Cheri Cagle, WVA Stakeholder Liaison

II. Summary of Actions Taken and/or Recommended

Actions Taken (votes adopted)

- i. To approve the October 12, 2023 meeting minutes.

III. Minutes

Welcome & Introduction

Ms. Zell called the meeting to order at 1:04 p.m. and provided the notice of recording. Ms. Zell asked Mr. Long to introduce himself.

Action Items

Dr. Dunn asked for a motion to approve the previous meeting's minutes. Upon motion duly made and seconded, it was unanimously

VOTED: To approve the October 12, 2023 meeting minutes.

Financial Updates

Mr. Miller provided a summary of the unaudited financials through September 30, 2023. The current cash position, including investments and cash equivalents, is \$29.3M as reported on the balance sheet. There has been a continued decline of reserves over the last 10 months due to both the cash reduction strategy approved in April, and the use of reserves to fund both COVID-19 vaccines and the nirsevimab monoclonal antibody. Mr. Miller noted that October financials were sent Tuesday and have similar trends to the September 2023 financials. He stated that as of today, there is approximately \$24M between KeyBank and Morgan Stanley, which is \$11M below April 2023 forecast. Mr. Miller stated that while the board approved \$14.5M for nirsevimab funding, only \$5.6M has been funded due to supply chain issues with the manufacturer.

Grid Projections

Ms. Zell and Mr. Miller provided an update on Grid projections and noted that based on the latest projection packet provided from the WA Department of Health (DOH) yesterday, the WVA assessment grid will see a significant increase between FY2024 and FY2025. Upon initial inspection of the projection packet, Mr. Miller stated the DOH projects:

- Total expenditures of \$114M in FY2024 and \$129M in FY2025; vaccine costs will have increased by 136% between FY2014 and FY2025 and by 34% between FY2023 and FY2025.
- \$5.6M will be expended on nirsevimab in FY2024 and \$14.7M in FY2025.

- \$13.3M will be expended on COVID vaccines in FY2024 and \$17.2M in FY2025.

Mr. Miller stated that he would like to provide the full board with an end of year cash projections memorandum for FY2024 and FY2025. The projections would include data from the November 2023 financial statements, the information in the DOH's new projection packet, and information regarding COVID vaccine and nirsevimab uptake rates. He further stated that there will be additional utilization data and revised DOH projections by the time the assessment grid is finalized in April. Dr. Harvey asked if the projection packet included any assumptions related to the maternal RSV vaccine ABRYSSVO. Mr. Miller did not have that information but agreed he would ask the DOH. The committee agreed that the end of year analysis would be prudent.

Stakeholder Coordination – Legislation

Mr. Long provided an update on the proposed bill's activities occurring now in advance of the legislative session which begins January 8, 2024. The strategy is to have two identical bills presented simultaneously – one in the Senate and one in the House. Mr. Long and his team will spend the next month speaking to stakeholders about the bills that will be proposed prior to them being submitted to both chambers. Dr. Harvey let Mr. Long know that she was willing to testify with advance notice.

Leakage Analysis and Inpatient Assessment Workgroup

Ms. Zell stated that well in advance of the expected statutory change, the WVA is working on a solution for ensuring inpatient settings receiving state-supplied vaccine are compliant with the dosage-based assessment (DBA). Ms. Zell noted that the DOH has committed to providing the data required to complete a comprehensive leakage analysis, including both inpatient hospital facilities and direct care practices. An Inpatient Assessment Workgroup has been established and held its first meeting on November 28, 2023. The group is comprised of WVA staff, DOH staff, payers, and providers. Additional payer and hospital system representatives are being recruited. Mr. Miller stated that the workgroup examined two assessment options and determined that the DBA made the most sense. The workgroup reviewed a set of issues, provided comments, and recommended a set of next steps. Meeting minutes will be sent tomorrow, and the next meeting of the workgroup is not yet scheduled. Ms. Zell asked if any of the Executive Committee members would be willing to review a list of providers to see if they had high-level contacts for outreach purposes. Mr. stated that he would send the list of providers to the committee members.

IV. Executive Session – Confidential.

V. Closing

The meeting concluded at 1:40 p.m.